Industry Veteran Jonathan Freeman, Ph.D. Joins ARTBIO As Chief Business Officer [Yahoo! Finance]
Baxter International Inc. (BAX)
Last baxter international inc. earnings: 4/30 07:15 am
Check Earnings Report
US:NYSE Investor Relations:
investor.baxter.com
Company Research
Source: Yahoo! Finance
Dr. Freeman will shape corporate business development and strategic partnerships CAMBRIDGE, Mass. Jan. 6, 2026 /PRNewswire/ -- ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of Pb alpha radioligand therapies (ARTs), announced the appointment of Jonathan Freeman, Ph.D. as Chief Business Officer. Dr. Freeman brings more than 25 years of healthcare and leadership experience to ARTBIO. In this newly created role, he will oversee ARTBIO's corporate business development and partnerships needed to support the company's increasing clinical and operational plans. As Chief Business Officer, Dr. Freeman will also serve as a member of the management team. "The next 18 months will be a vital period of growth as we expand our clinical and manufacturing operations globally, and our pipeline," said Emanuele Ostuni, CEO of ARTBIO. "I'm delighted to have Jonathan join us at this critical time. His wealth of industry experience will be invaluable to me
Show less
Read more
Impact Snapshot
Event Time:
BAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAX alerts
High impacting Baxter International Inc. news events
Weekly update
A roundup of the hottest topics
BAX
News
- Baxter International (NYSE:BAX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $22.00 to $23.00. They now have a "neutral" rating on the stock.MarketBeat
- Baxter Introduces the Dynamo Series, a New Smart Stretcher to Help Address Common Challenges in Hospital SettingsBusiness Wire
- Does Baxter International (BAX) Now Look Fairly Priced After Multi-Year Share Price Slide [Yahoo! Finance]Yahoo! Finance
- Intravenous (IV) Solutions Market Size to Reach USD 25.10 Billion by 2033, Growing at a CAGR of 8.24% - SNS Insider [Yahoo! Finance]Yahoo! Finance
- Baxter International (NYSE:BAX) had its price target lowered by analysts at Barclays PLC from $36.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
BAX
Earnings
- 10/30/25 - Beat
BAX
Sec Filings
- 12/22/25 - Form 8-K
- 12/16/25 - Form 4
- 12/10/25 - Form 3
- BAX's page on the SEC website